Treatment Outcomes of Partial Gland Ablation for Prostate Cancer: Evaluating PSA, MRI, Ultrasound, and Biopsy Metrics

No results found.

Following focal therapy (FT) for prostate cancer (PCa), a study aimed to determine whether changes in MRI or PSA levels could effectively replace biopsy for assessing treatment outcomes. The research involved 309 men with Grade Group 2 (GG2) or Grade Group 3 (GG3) PCa who underwent FT between 2016 and 2022, specifically utilizing High-Intensity Focused Ultrasound (HIFU) or cryotherapy. Baseline, 6-month, and 18-month follow-up assessments included MRI-guided biopsy (MRGB), targeted, and systematic biopsies to evaluate the presence of clinically significant PCa (csPCa). At the 6-month follow-up, 261 men completed biopsies, revealing that 72% of them had successful FT with no csPCa, while 28% had failed treatment. MRI lesions were no longer visible in 79% of successful cases, while 72% of the failures still exhibited lesions. Although PSA levels decreased by more than 50% in a majority of both successful and failed treatments, the differences were not statistically significant. The study found that MRI had a sensitivity of 28% and specificity of 79%, while PSA showed a sensitivity of 46% and specificity of 67%. The combined sensitivity of using both MRI and PSA to suggest the absence of csPCa was 73% with a specificity of 75%. Ultimately, the findings indicate that the presence of residual csPCa is more accurately determined by MRGB rather than relying on PSA or MRI metrics, highlighting that FT may have a suppressive effect on prostate markers independent of its anti-neoplastic impact.

Treatment Outcomes of Partial Gland Ablation for Prostate Cancer: Evaluating PSA…

by Echo Writer time to read: 1 min
0

Contact Support

If you're interested in posting an article and need assistance, please don't hesitate to contact our support team. We're here to help you through the process, answer any questions you may have, and ensure that your article is published smoothly and effectively.

support@ehealthcommunity.org